A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Inclusion Criteria:
Exclusion Criteria:
Subretinal hemorrhage, fibrosis, or atrophy of > 50% of the total lesion area and/or that involves the fovea in the study eye
Uncontrolled glaucoma in the study eye
Aphakia or pseudophakia with AC-IOL in the study eye
Active intraocular inflammation in the study eye
Any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye
History of rhegmatogenous retinal detachment in the study eye
Any current or history of ocular disease other than nAMD in the study eye that may confound assessment of the macula or affect central vision
History of the following therapies in the study eye:
Any current or history of endophthalmitis in either eye
History of idiopathic or autoimmune-associated uveitis in either eye
Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
St. Petersburg, Florida 33711, United States
Austin, Texas 78705, United States
Kita-gun, Kanagawa 761-0793, Japan
Nakagami-gun, Okinawa 903-0215, Japan
Bunkyō, Tokyo 113-8655, Japan
Seoul, Seoul Teugbyeolsi 06591, South Korea